Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck Millipore Announces New Genomic Biomarker Services

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Genetic and epigenetic technologies added to established CRO services for biomarker development, validation and testing.

Merck Millipore's Discovery and Development Solutions business, part of the Life Science division of Merck, has announced that it will now offer genomic biomarker services to aid drug companies in targeting patient sub-groups for improved clinical outcomes, understanding drug safety and efficacy, and characterizing tumors.

The new qPCR and pyrosequencing-based services add to the company's existing protein- and cell-based solutions, which include ELISA, multiplex and flow cytometry platforms, as well as its extensive experience in assay development, validation and sample testing.

By enabling both genomic biomarker analysis as well as cross-platform biomarker validation, Merck Millipore can help customers improve their research and development pipeline decisions.

Demonstrating the value of Merck Millipore Biomarker Services, which now links genomic, protein-based, and cell-based technologies, scientists at Merck Millipore recently profiled transcription in gefitinib-treated non-small cell lung cancer (NSCLC) cells by qRT-PCR.

The genotypic and mRNA expression data were then cross-validated with protein expression using flow cytometry and multiplex assays, solidifying the connection between the genotype and phenotype of interest.

These types of connections provide confidence to preclinical and clinical decision-makers regarding drug safety and efficacy.

"The drug development process is undergoing a paradigm shift from a 'one size fits all' model to 'Precision Medicine,'" says Christina Shasserre, Vice President of Discovery and Development Services at Merck Millipore.

Shasserre continued, "Genomic information remains a critical part of this transformation. At Merck Millipore, we have the platforms, the scientific expertise and the experience running assays to help our customers develop their genomic biomarkers and enable them to successfully deliver on this new paradigm."

Merck Millipore Discovery and Development Solutions, with sites in Dundee and Oxford, UK and St. Louis, Missouri, USA, is a leading provider of outsourced discovery and bioanalytical services, focusing on the development of biotherapeutics.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novel Mechanism for Activation of SIRT1
Assay format allows for simple, sensitive detection of sirtuin activity on any desired substrate.
Wednesday, April 24, 2013
Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
Enables accelerated process development and production of proteins/monoclonal antibodies.
Friday, September 21, 2012
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos